In their study, treatment with Zidovudine (ZVD) and Didanosine
(DDI) did not result in loss of hearing, even after taking into account noise exposure, immune status and age.
and stavudine became available for US$1 per day.
Under the terms of the agreement, Matrix Laboratories will secure World Health Organization (WHO) prequalification for all products covered by the agreement, including pediatric formulations of didanosine
and, in the future, atazanavir powder formulation for pediatric use when Bristol-Myers Squibb's product is available.
Over an 18-year period, the FDA's Adverse Event Reporting System received 42 reports of noncirrhotic portal hypertension in patients aged 10-66 years taking didanosine
(Videx, Bristol-Myers Squibb) or the delayed-release formulation (VidexEC).
Over an 18-year period, the FDKs Adverse Event Reporting System received 42 reports of non-cirrhotic portal hypertension in patients ages 10 to 66 years taking didanosine
(marketed as Videx) or the delayed-release formulation (marketed as Videx EC).
Interestingly, the use of abacavir, but not of didanosine
, was associated with higher baseline levels of the inflammatory biomarkers hsCRP and IL-6.
This distinguishes it from the prolonged damage that may occur due to the protracted accumulation of toxic metabolites of drugs like pentamidine, valproic acid and didanosine
Bristol-Myers Squibb sends a warning letter to healthcare providers regarding pancreatitis with the NRTI didanosine
For example, didanosine
and stavudine concentrations drop to subtherapeutic levels when these drugs are taken with methadone.
In December 2004, the FDA approved a generic version of Didanosine
(ddl) Delayed Release capsules (200 mg, 250 mg, and 400 mg) to use in combination with other HIV needs to treat adults with HIV.
Severe hepatotoxicity occurred in patients on zidovudine (ZDV), lamivudine (3TC), or nevirapine (NVP) and with antiretroviral regimens containing didanosine
(ddI) or stavudine (d4T).
Thai AIDS activists had sued to challenge the validity of a patent on the formulation of didanosine
(ddI), used as a component of the lifesaving drug cocktail for people with AIDS.
Seven patients were receiving a stavudine-containing regimen, and one was receiving a combination of stavudine and didanosine
, or both as the initial treatment for symptomatic HIV-infected children: AIDS Clinical Trials Group (ACTG) Study 152 Team.
In early October, Thailand's intellectual property rights court ruled that an amendment to a patent held by Bristol-Myers Squibb for didanosine
(ddI) was invalid.